Delivery Order HT942523D0011-HT942524F0269
Award Date
9/20/24
Potential Completion Date
9/19/25
Potential Value
$1.9M
Federal Agency
Defense Health Agency
Awardee
Eitr Biologics, Inc.
Ultimate Awardee
Not listed
PSC Category
AJ11 - General Science And Technology R&D Services; General Science And Technology; Basic Research
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $750,000.00 firm fixed price delivery order awarded by the Defense Health Agency (DHA) to Eitr Biologics, Inc. for the development of novel nanotherapeutic approaches for the treatment of pneumonic plague. The order is part of a larger $4.39 million Indefinite Delivery Vehicle (IDV) contract between Eitr Biologics and DHA to advance the research and development of nanotherapeutics to combat biological threats. The work will be performed in San Diego, California and involves assessing...
This is a $311,106,669.70 cost-plus-fixed-fee contract awarded to Eitr Biologics, Inc. by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the Department of Health and Human Services. The contract is for the development of a multimodal antibody platform to extend the window of immunotherapeutic intervention against viral infections. This long-term contract, with a performance period through September 2030, is not set aside. Eitr Biologics is a for-profit...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This is a $979,538.00 Firm Fixed Price Delivery Order contract awarded to Altimmune, Inc., a for-profit organization, by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response. The contract, which was not set aside, is for the development of vaccine formulations effective against NIAID priority pathogens, evaluation of clone generation and stability, biodefense vaccine enhancement, and general biomedical research. Altimmune, Inc....
This federal contract award was made by the Defense Health Agency (DHA) to Erivan Bio, LLC, a for-profit limited liability company, for a Small Business Technology Transfer (STTR) Phase I research project titled "Novel Scalable Loading of Antibiotics in Exosomes for Bacterial Wound Infection Prevention". The contract has a firm fixed price of $249,981.86 and a completion date of September 22, 2024. This STTR Phase I award supports research and development to develop a novel approach...
This federal contract award, valued at $43,027,525.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to Hawaii Biotech, Inc. (HBI), a biotechnology company focused on research and development of vaccines and therapeutics for infectious diseases. The contract is for the "DEVELOPMENT OF A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS." It is a definitive, cost-plus-fixed-fee contract with a completion date of December 30, 2025....
This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...
This is a $299,959 SBIR Phase I contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a biopharmaceutical company that develops drugs and vaccines for cancer, infectious diseases, and other unmet medical needs. The contract is for research, development, testing, and manufacturing services related to HDT Bio Corp's RNA technologies, adjuvants, antibodies, nanoparticles, and other platforms to create new medical...
The U.S. Defense Health Agency (DHA) awarded a $249,993.28 Small Business Innovation Research (SBIR) Phase I firm-fixed-price purchase order to Glyphic Biotechnologies, Inc., a minority-owned, small disadvantaged business, for the development of anti-glycan antibodies against multi-drug resistant ESKAPE wound pathogens. The contract has a completion date of November 7, 2024 and was awarded on April 8, 2024. Glyphic Biotechnologies is a biotechnology startup focused on developing...
This is a $3,007,557.97 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of new platform technologies for viral and therapeutic evolution assays under DARPA's Small Business Innovation Research (SBIR) Program Phase II. The contract has a firm fixed price pricing type and a period of performance through November 2022. Autonomous Therapeutics has also...